Abivax
Abivax develops innovative treatments modulating the body’s natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer. As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and other inflammatory diseases (ABX464) as well as liver cancer (ABX196). Our mission is to utilize Abivax’s drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Clinical Services
- Market Focus:
- Nationally (across the country)
About Us
Abivax is developing therapies that modulate the body’s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat chronic inflammatory diseases, viral diseases, and cancer.
Its lead clinical candidate, ABX464, has demonstrated strong clinical anti-inflammatory effects in ulcerative colitis.